For the Inventor, By the Inventor

Enter inventor name

Eschborn, Germany

Wolfgang Scholz

USPTO Granted Patents = 52 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 5.9

ph-index = 13

Forward Citations = 476(Granted Patents)

Forward Citations (Not Self Cited) = 364(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

47 out of 6,662

Hoechst Aktiengesellschaft

Aventis Pharma Deutschland, Gmbh

Hoeschst Aktiengesellschaft

Meck Patent Gmbh

Years Active: 1992-2019

Loading Chart...

Loading Chart...

Areas of Expertise:

Pharmaceutical Composition

Guanidines

Insulin Resistance

Cardiovascular Diseases

Diagnostic Aid

Benzoylguanidines

Alkenylcarboxylic Acid

Heterocyclic Compounds

Cardioprotective Agents

Amino Acid Substituted

Antiarrhythmic Agents

Sulfonylamino Compounds

52 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10292949 - Pharmaceutical composition comprising rimeporide for treating diseases associated with insulin resistance and β-cell dysfunction (2019-05-21),

2. 6632840 - Monoacyl-substituted guanidines, a process for their preparation, their use as a medicament or diagnostic aid, and pharmaceutical compositions containing them (2003-10-14),

3. 6504057 - Fluorophenyl-substituted alkenylcarboxylic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them (2003-01-07),

4. 6436999 - Diacyl-substituted guanidines, a process for their preparation, their use as medicine or diagnostic aid, and medicine containing them (2002-08-20),

5. 6348476 - Pharmaceutical combination preparation of an inhibitor of the sodium/hydrogen exchanger and a medicament for the treatment of cardiovascular diseases (2002-02-19),

6. 6262123 - Ortho-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them (2001-07-17),

7. 6156800 - 4-fluoroalkyl-substituted benzoylguanidines, process for their (2000-12-05),

8. 6153651 - Ortho-substituted benzoylguanidines, process for their preparation, (2000-11-28),

9. 6093729 - Substituted bicyclic heteroaroylguanidines, a process for their (2000-07-25),

10. 6075054 - Ortho-substituted benzoylguanidines, process for their preparation, (2000-06-13),

11. 6057322 - Basically-substituted benzoylguanidines, a process for preparing them, (2000-05-02),

12. 6025349 - Phenyl.-substituted alkenylcarboguanidides carrying perfluoroalkyl (2000-02-15),

13. 6022899 - Substituted benzyloxy-carbonylguanidines, a process for their (2000-02-08),

14. 6011063 - Ortho-substituted benzoylguanidines, process for their preparation, (2000-01-04),

15. 6005010 - Phenyl-substituted alkenylcarboxylic acid guanidides, process for their (1999-12-21),

Title: The Innovative Legacy of Wolfgang Scholz

Introduction: Wolfgang Scholz, a prolific inventor hailing from Eschborn, Germany, has carved a remarkable path in the field of pharmaceutical innovations. With an impressive portfolio of 52 patents, Scholz's contributions have significantly impacted the treatment of various diseases, particularly those associated with insulin resistance and β-cell dysfunction.

Latest Patents: Among his latest patents is a groundbreaking pharmaceutical composition comprising rimeporide for treating diseases linked to insulin resistance and β-cell dysfunction. This invention offers promising solutions for Type II diabetes mellitus, the Metabolic syndrome, diabetic nephropathy, and neuropathy. Scholz's work also includes the development of monoacyl-substituted guanidines, showcasing his dedication to advancing medical solutions for complex health conditions.

Career Highlights: Wolfgang Scholz has lent his expertise to reputable companies such as Hoechst Aktiengesellschaft and Aventis Pharma Deutschland, Gmbh. His tenure with these organizations has been marked by innovative breakthroughs and a relentless pursuit of excellence in pharmaceutical research and development.

Collaborations: Throughout his career, Scholz has collaborated closely with esteemed peers such as Udo Albus and Andreas Gerhard Weichert. Together, they have synergized their talents to drive forward cutting-edge projects and bring transformative ideas to fruition in the competitive landscape of pharmaceutical innovation.

Conclusion: Wolfgang Scholz's unwavering dedication to advancing medical science through his inventive spirit and collaborative efforts sets a shining example in the realm of pharmaceutical innovations. His legacy serves as a testament to the transformative power of innovation in revolutionizing healthcare practices and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…